000289140 001__ 289140
000289140 005__ 20240526011255.0
000289140 0247_ $$2doi$$a10.17879/FREENEUROPATHOLOGY-2024-5345
000289140 0247_ $$2pmid$$apmid:38532825
000289140 0247_ $$2pmc$$apmc:PMC10964111
000289140 0247_ $$2altmetric$$aaltmetric:163364680
000289140 037__ $$aDKFZ-2024-00607
000289140 041__ $$aEnglish
000289140 082__ $$a610
000289140 1001_ $$0P:(DE-HGF)0$$aReuss, David E$$b0$$eFirst author
000289140 245__ $$aHeterogeneity of DNA methylation profiles and copy number alterations in 10782 adult-type glioblastomas, IDH-wildtype.
000289140 260__ $$aMuenster$$bProf. Dr. Werner Paulus, University of Muenster, Institute of Neuropathology$$c2024
000289140 3367_ $$2DRIVER$$aarticle
000289140 3367_ $$2DataCite$$aOutput Types/Journal article
000289140 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1716369423_7220
000289140 3367_ $$2BibTeX$$aARTICLE
000289140 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000289140 3367_ $$00$$2EndNote$$aJournal Article
000289140 500__ $$a#EA:B300#LA:B300# / 2024 Mar 22:5:5-7
000289140 520__ $$aThe morphological patterns leading to the diagnosis of glioblastoma may also commonly be observed in several other distinct tumor entities, which can result in a mixed bag of tumors subsumed under this diagnosis. The 2021 WHO Classification of CNS Tumors has separated several of these entities from the diagnosis of glioblastoma, IDH-wildtype. This study determines the DNA methylation classes most likely receiving the diagnosis glioblastoma, IDH wildtype according to the definition by the WHO 2021 Classification and provides comparative copy number analyses. We identified 10782 methylome datasets uploaded to the web page www.molecularneuropathology.org with a calibrated score of ≥0.9 by the Heidelberg Brain Tumor Classifier version v12.8. These methylation classes were characterized by the diagnosis glioblastoma being the most frequent classification encountered in each of the classes according to the WHO 2021 definition. Further, methylation classes selected for this study predominantly contained adult patients. Unsupervised clustering confirmed the presence of nine methylation classes containing tumors most likely receiving the diagnosis glioblastoma, IDH-wildtype according to the WHO 2021 definition. Copy number analysis and a focus on genes with typical numerical alterations in glioblastoma revealed clear differences between the nine methylation classes. Although great progress in diagnostic precision has been achieved over the last decade, our data clearly demonstrate that glioblastoma, IDH-wildtype still is a heterogeneous group in need of further stratification.
000289140 536__ $$0G:(DE-HGF)POF4-312$$a312 - Funktionelle und strukturelle Genomforschung (POF4-312)$$cPOF4-312$$fPOF IV$$x0
000289140 588__ $$aDataset connected to DataCite, PubMed, , Journals: inrepo02.dkfz.de
000289140 650_7 $$2Other$$a7/10 signature
000289140 650_7 $$2Other$$aAmplification
000289140 650_7 $$2Other$$aCDKN2A/B
000289140 650_7 $$2Other$$aCNV
000289140 650_7 $$2Other$$aClassification
000289140 650_7 $$2Other$$aCopy Number Variations
000289140 650_7 $$2Other$$aEGFR
000289140 650_7 $$2Other$$aGlioblastoma
000289140 650_7 $$2Other$$aHomozygous deletion
000289140 650_7 $$2Other$$aMethylation
000289140 7001_ $$0P:(DE-He78)e54a1e0999c1d8c95869ef9188b794cc$$aSchrimpf, Daniel$$b1$$udkfz
000289140 7001_ $$0P:(DE-HGF)0$$aCherkezov, Asan$$b2
000289140 7001_ $$0P:(DE-He78)c77fccff3e6c42b017b2e8a09813590c$$aSuwala, Abigail K$$b3$$udkfz
000289140 7001_ $$0P:(DE-He78)5497d0db009ca23fed3a604a72280bb3$$aLausová, Tereza$$b4$$udkfz
000289140 7001_ $$aSnuderl, Matija$$b5
000289140 7001_ $$0P:(DE-He78)51bf9ae9cb5771b30c483e5597ef606c$$aCapper, David$$b6$$udkfz
000289140 7001_ $$0P:(DE-He78)45440b44791309bd4b7dbb4f73333f9b$$aSill, Martin$$b7$$udkfz
000289140 7001_ $$0P:(DE-He78)551bb92841f634070997aa168d818492$$aJones, David T W$$b8$$udkfz
000289140 7001_ $$0P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9$$aPfister, Stefan M$$b9$$udkfz
000289140 7001_ $$0P:(DE-He78)a1f4b408b9155beb2a8f7cba4d04fe88$$aSahm, Felix$$b10$$udkfz
000289140 7001_ $$0P:(DE-He78)a8a10626a848d31e70cfd96a133cc144$$avon Deimling, Andreas$$b11$$eLast author$$udkfz
000289140 773__ $$0PERI:(DE-600)3004697-X$$a10.17879/FREENEUROPATHOLOGY-2024-5345$$gVol. 5$$n7$$p5-7$$tFree Neuropathology$$v5$$x2699-4445$$y2024
000289140 909CO $$ooai:inrepo02.dkfz.de:289140$$pVDB
000289140 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000289140 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)e54a1e0999c1d8c95869ef9188b794cc$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000289140 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000289140 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c77fccff3e6c42b017b2e8a09813590c$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000289140 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)5497d0db009ca23fed3a604a72280bb3$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000289140 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)51bf9ae9cb5771b30c483e5597ef606c$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000289140 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)45440b44791309bd4b7dbb4f73333f9b$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000289140 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)551bb92841f634070997aa168d818492$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000289140 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9$$aDeutsches Krebsforschungszentrum$$b9$$kDKFZ
000289140 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a1f4b408b9155beb2a8f7cba4d04fe88$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000289140 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a8a10626a848d31e70cfd96a133cc144$$aDeutsches Krebsforschungszentrum$$b11$$kDKFZ
000289140 9131_ $$0G:(DE-HGF)POF4-312$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunktionelle und strukturelle Genomforschung$$x0
000289140 9141_ $$y2024
000289140 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-08-24
000289140 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-08-24
000289140 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-08-24
000289140 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2022-02-17T12:33:40Z
000289140 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2022-02-17T12:33:40Z
000289140 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2022-02-17T12:33:40Z
000289140 9202_ $$0I:(DE-He78)B300-20160331$$kB300$$lKKE Neuropathologie$$x0
000289140 9201_ $$0I:(DE-He78)B300-20160331$$kB300$$lKKE Neuropathologie$$x0
000289140 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x1
000289140 9201_ $$0I:(DE-He78)BE01-20160331$$kBE01$$lDKTK Koordinierungsstelle Berlin$$x2
000289140 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lB062 Pädiatrische Neuroonkologie$$x3
000289140 9201_ $$0I:(DE-He78)B360-20160331$$kB360$$lPädiatrische Gliomforschung$$x4
000289140 9200_ $$0I:(DE-He78)B300-20160331$$kB300$$lKKE Neuropathologie$$x0
000289140 980__ $$ajournal
000289140 980__ $$aVDB
000289140 980__ $$aI:(DE-He78)B300-20160331
000289140 980__ $$aI:(DE-He78)HD01-20160331
000289140 980__ $$aI:(DE-He78)BE01-20160331
000289140 980__ $$aI:(DE-He78)B062-20160331
000289140 980__ $$aI:(DE-He78)B360-20160331
000289140 980__ $$aUNRESTRICTED